Liquidia Technologies

Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. The company has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia is also developing L606, an investigational liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer. Its subsidiary Liquidia PAH provides commercialization of pharmaceutical products to treat pulmonary disease, including generic Treprostinil Injection. The company leverages its proprietary PRINT® (Particle Replication In Nonwetting Templates) technology platform to engineer precise drug particles for enhanced efficacy, tolerability, and convenience.